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Abstract
Aims/hypothesis Pre-eclampsia is a pregnancy-specific multi-
system disorder and a state of physiological insulin resistance.
Our aim was to systematically evaluate and quantify the evi-
dence on the relationship between pre-eclampsia and the fu-
ture risk of diabetes.
Methods We conducted a systematic review and meta-
analysis of studies that evaluated diabetes in women
with and without pre-eclampsia. We performed a sys-
tematic search of MEDLINE and EMBASE to identify
relevant studies. Independent double data extractions
were conducted by four reviewers. Random-effects me-
ta-analysis was used to estimate the risk of future dia-
betes following pre-eclampsia.
Results A total of 21 studies were identified with more than
2.8 million women, including more than 72,500 women with
pre-eclampsia. Meta-analysis of studies that adjusted for po-
tential confounders demonstrated that pre-eclampsia was in-
dependently associated with an increased risk of future diabe-
tes (RR 2.37 [95% CI 1.89, 2.97]). This risk appeared in
studies that followed women from less than 1 year postpartum
(RR 1.97 [95% CI 1.35, 2.87]) and persisted to more than
10 years postpartum (RR 1.95 [95% CI 1.28, 2.97]). After
adjusting for BMI or gestational diabetes, pre-eclampsia
remained linked with an increased risk of future diabetes
(RR 2.38 [95% CI 1.74, 3.24] and RR 2.36 [95% CI 1.94,
2.88], respectively).
Conclusions/interpretation Pre-eclampsia is independently
associated with a twofold increase in future diabetes.
Our study highlights the importance of clinical risk as-
sessment for the future development of diabetes in
women with pre-eclampsia. We recommend detailed
evaluation of a screening programme for diabetes in this
high-risk population.
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Introduction
Pre-eclampsia is a pregnancy-specific multisystem disorder
that affects 5–8% of pregnancies [1]. It frequently manifests
as new-onset hypertension and proteinuria. It is the most com-
mon cause of severe perinatal morbidity and is responsible for
more than 50,000 maternal deaths per annum globally [2].
Pregnancy is known to be a state of physiological insulin
resistance and relative glucose intolerance [3]. Insults to the
cardiovascular and renal systems from pre-eclampsia often
persist postnatally, with insulin resistance [4], diffuse vascular
endothelial dysfunction [5] and inflammatory factor activation
[6] reported, although it is unclear whether these are pre-
existing conditions prior to the pregnancy or longer-term se-
quelae of pre-eclampsia. Many of these pathophysiological
mechanisms are also linked to the future development of dia-
betes [7]. Furthermore, lower insulin sensitivity and higher
insulin levels have been found in women with a previous
history of pre-eclampsia [8].
It remains controversial as to whether pre-eclampsia has
long-termmetabolic sequelae and is an independent risk factor
for the future development of diabetes, as it is difficult to
separate pre-eclampsia from confounding factors that are as-
sociated with future incident diabetes. The existing literature
provides conflicting data, with some studies showing signifi-
cant increases in the risk of future diabetes [9, 10] and others
not observing such a relationship [11, 12]. Many of the studies
that have focussed on the association between pre-eclampsia
and future incident diabetes have reported limited clinical de-
tails for the cohorts studied, and have not adjusted for BMI
[9], family history of diabetes [10] or other factors that are
known to increase the future risk of incident diabetes, hence
raising the potential for unmeasured or unreported con-
founders contributing to the associations reported. This sys-
tematic review and meta-analysis aimed to quantify the risk of
diabetes in later life following pre-eclampsia in pregnancy.
Here, we provide an overview of the relevant studies and of
the association between pre-eclampsia and future incident
diabetes.
Methods
Eligibility criteriaWe selected studies that evaluated diabetes
in women with and without pre-eclampsia. Diabetes could be
type 1, type 2, any diabetes or the use of diabetes medications
such as insulin or oral antidiabetic agents. There were no re-
strictions on the definition of pre-eclampsia. Included studies
had to have at least two groups (one with and one without pre-
eclampsia) and to provide results that allowed risk estimates to
be calculated. Studies were included if they evaluated some
form of risk or odds (e.g. RR, HR, OR) that measured the
association with diabetes in patients with or without pre-
eclampsia, or reported crude results that enabled calculation
of an RR. Crude results that met these criteria had to evaluate
diabetes patients or total participants with pre-eclampsia, or
diabetes patients or total participants without pre-eclampsia.
We planned to contact authors to clarify results where the data
reported were uncertain, but all of the studies that met the
inclusion criteria had clear reporting of results. There were
no restrictions on study design or cohort type. We excluded
publications that were not published in the English language.
Data sources and searches We searched MEDLINE and
EMBASE using Ovid SP for studies from 2005 to August
2015 (see electronic supplementary material [ESM] Methods
for comprehensive search terms). This is because the diagnos-
tic criteria for both pre-eclampsia [13] and diabetes [14] were
changed in 2001 and 2006, respectively. The relevant primary
studies for inclusion in this analysis were drawn from a com-
prehensive programme of evidence synthesis that explored the
association between pre-eclampsia and adverse cardiovascular
or metabolic outcomes. We also examined the reference lists
of relevant studies and reviews for additional studies that
might meet the inclusion criteria.
Study selection and data extraction Four reviewers (PW,
RH, RAK,AB) screened all of the titles and abstracts retrieved
from the search to identify studies that met the inclusion
criteria. The full manuscripts of studies that potentially met
the inclusion criteria were reviewed, and the final decision to
include or exclude studies was made with two other reviewers
(CSK, MAM). Independent double extractions were per-
formed by four reviewers (PW, RH, RAK, AB), and data were
collected on study design, year, country, number of women,
mean age, parity, cohort characteristics, definition of pre-
eclampsia, outcomes assessed, timing of assessment and
results.
Study quality assessment We assessed the quality of the
studies using the Newcastle–Ottawa Scale [15]. The represen-
tativeness of the exposed cohort was based on whether the
study only evaluated patients of a subgroup of the general
population, thus limiting generalisability compared with the
general female population. Selection of the non-exposed co-
hort was considered by evaluating whether members of refer-
ence or comparator group without pre-eclampsia were includ-
ed based on a specific criteria, or were a non-selected group.
Ascertainment of exposure was evaluated by considering the
likelihood that cases were misclassified as having pre-
eclampsia when they did not, or that cases were wrongly clas-
sified as not having pre-eclampsia. The methods for studies
where all patients were assessed for pre-eclampsia were
deemed to be more reliable. Studies that excluded patients
with baseline diabetes were considered to be more reliable in
terms of demonstrating that the outcome of interest was not
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present at the start of the study. The comparability of the
cohort was considered by whether the study had baseline dif-
ferences between the groups with and without pre-eclampsia,
and whether the analysis matched or adjusted for these differ-
ences. Higher quality studies either did not have differences in
baseline characteristics or adjusted for differences in these
characteristics. Assessment of outcome was considered a
quality criterion, where the highest quality was an indepen-
dent blind assessment, followed by record linkage. Outcome
assessments were considered to be low quality if there were
self-reported results or no description of the results. Duration
of follow-up was another quality indicator where a study was
deemed high quality if it followed up patients for more than
10 years. The final quality assessment area was the adequacy
of follow-up, which was deemed to be high if all participants
were accounted for and followed, with loss to follow-up of
less than 10%. Studies were considered to be low quality in
this area if loss to follow-up was more than 10% or if no
statement regarding follow-up was provided. We planned to
conduct asymmetry testing for publication bias provided there
were more than ten studies in the meta-analysis and statistical
heterogeneity was less than 50% [16].
Data synthesis and analysis We used Review Manager
(RevMan) [Computer program] version 5.3.5 (Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014) to conduct random-effects meta-analysis using the in-
verse variance method for pooling log RRs. We used ran-
dom effects because the studies were conducted in a wide
range of settings in different populations, making it neces-
sary to take heterogeneity into account for the pooled effect
estimate. Where possible, we chose to pool adjusted risk
estimates from primary studies; where these data were not
available, raw data were used to calculate unadjusted risk
estimates. The primary outcome was any diabetes and the
analysis was performed considering adjusted and unadjusted
groups separately. Secondary analysis was performed con-
sidering the risk of types 1 and 2 diabetes separately.
Statistical heterogeneity was assessed using the I2 statistic,
where I2 values of 30–60% represented a moderate level of
heterogeneity [17]. Where there was moderate or a greater
degree of heterogeneity, we performed leave-one-out analy-
sis to identify studies that contributed to a high degree of
heterogeneity. Sensitivity analysis was performed consider-
ing the follow-up of the studies for diabetes (<1, 1–5, 6–10
and >10 years), exclusion of women with baseline diabetes
and hypertension, and baseline differences in BMI, age and
gestational diabetes. For the sensitivity analysis on gestation-
al diabetes, in cases where there were more than two sepa-
rate groups being studied, we selected the group with no
pre-eclampsia vs the group with pre-eclampsia but no ges-
tational diabetes for data abstraction.
Results
Description of studies included in analysis The process of
study selection is shown in Fig. 1. Out of 10,724 titles and
abstracts screened, there were 21 relevant studies including a
total of 2,883,658 women (range 140–948,035 women in each
study). The study designs and participant demographics are
shown in ESM Table 1. There were 72,860 women with pre-
eclampsia and 1,961,159 women without pre-eclampsia from
20 studies that reported the numbers of women in each group.
Four studies were of primiparous women [18–21] and 17were
of women of any parity [9–12, 18, 22–33]. The mean age of
the women ranged from 23.4 to 31 years at index pregnancy.
Quality assessment in included studies The quality assess-
ment of the included studies using the Newcastle–Ottawa
Scale [15] is shown in ESM Table 2 and 3. A total of 19
studies were deemed to have reliable methods for ascertaining
pre-eclampsia, which included review of medical charts, dis-
charge codes, national databases and other registries [9, 10,
12, 18–26, 28–34], while 18 used reliable methods for ascer-
taining diabetes, which included blood glucose testing, med-
ical records, direct assessment and use of insurance or registry
data [9, 10, 12, 18–28, 30, 32–34]. Loss to follow-up was less
than 10% in ten studies [9–11, 19, 22, 26, 28, 30, 32, 34]. An
adjusted analysis was used in 16 studies [9, 10, 18–25, 27–29,
32–34].
Determining pre-eclampsia and study results A variety of
different methods were used to ascertain pre-eclampsia. The
most common definition used was the 2014 definition of the
International Society of the Studies of Hypertension in
Pregnancy [35]. Follow-up for incident diabetes was up to
46 years. Results are shown in ESM Table 4.
Pooled analysis of pre-eclampsia and diabetesA total of 17
studies looked at the future risk of any diabetes (type 1 or 2) in
association with pre-eclampsia, ten of which adjusted for po-
tential confounders (Fig. 2a) [9, 10, 18, 20, 21, 23, 28, 29, 32,
33]. The confounders that were adjusted for in the analyses are
presented in ESM Table 3. The pooled results suggested a
significant increase in future incident diabetes risk associated
with pre-eclampsia (RR 2.21 [95% CI 1.86, 2.63], I2 =53%)
(Fig. 2a). The results were also statistically significant for the
studies that adjusted for baseline confounders (adjusted [a]RR
2.37 [95% CI 1.89, 2.97] I2=67%).
Fig. 2b shows the results of the pooled analysis for studies
of pre-eclampsia and types 1 and 2 diabetes. There was only
one study of type 1 diabetes, reported by Savitz et al in 2014
[22], in which there was no significant association between
pre-eclampsia and future incident type 1 diabetes. For incident
type 2 diabetes, however, there was a significant increase in
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risk associated with pre-eclampsia from four pooled studies
(RR 2.37 [95% CI 1.37, 4.10], I2=95%) [22, 24, 27, 34].
Sensitivity analysis for follow-up time and baseline diabe-
tes and hypertension exclusions Sensitivity analysis was
performed to consider the effect of follow-up time for diabetes
and exclusion of baseline diabetes and hypertension (Table 1).
There were three studies with less than 1 year of follow-up,
two studies with 1–5 years’ follow-up, nine studies with
6–10 years’ follow up and seven studies with more than
10 years’ follow-up (ESM Figs 1–4). For any diabetes, the
pooled results showed there was a greater risk of any diabetes
in women who had pre-eclampsia compared with those who
did not have pre-eclampsia when they were followed up from
less than 1 year postpartum, and this effect persisted beyond
10 years of follow-up (<1 year: RR 1.97 [95% CI 1.35, 2.87];
1–5 years: RR 2.99 [95% CI 2.44, 3.66]; 6–10 years: RR 2.62
[95% CI 1.96, 3.50]; and >10 years: RR 1.95 [95% CI 1.28,
2.97]).
We were able to examine studies for the risk of future type
2 diabetes only. This analysis showed that an increased risk of
type 2 diabetes was already apparent after a follow-up of less
than 1 year and persisted until 10 years, albeit the number of
studies was small. We then concentrated on studies that ex-
cluded either baseline diabetes or hypertension from the study
cohort. This showed a significantly increased risk in any dia-
betes in the pre-eclampsia group (diabetes exclusion: aRR
2.34 [95% CI 1.86, 2.93]; hypertension exclusion: aRR 2.40
[95%CI 1.97, 2.92]). The individual Forest plots are shown as
supplementary figures (ESM Figs 1–6).
Sensitivity analysis considering studies that adjusted for
BMI, age and gestational diabetes between the pre-
eclampsia and control groups We conducted sensitivity
analyses to consider the confounding factors of BMI, age
and gestational diabetes (Table 2).We were unable to examine
other important confounding factors due to the lack of studies
presenting such data. Following adjustment for BMI in the
pre-eclampsia and control groups, there was a significantly
increased risk of any diabetes in the pooled analysis (aRR
2.38 [95% CI 1.74, 3.24]) and of type 2 diabetes (aRR 2.53
[95% CI 1.64, 3.90]). This increased risk for any diabetes in
the pooled analysis remained in studies that also excluded
baseline hypertension and diabetes at recruitment (aRR 2.61
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Records identified through EMBASE 
and MEDLINE database searching 
between 2005 and August 2015  
(n=10,724)
Full-text articles excluded (n=45)
• Did not evaluate diabetes as an 
outcome (n=37)
• Studied pregnancy-induced 
hypertension rather than pre-
eclampsia (n=5)
• No control group (n=2)
• No diabetes events in study (n=1)
Full-text articles assessed for 
eligibility (n=66)
Title and abstract screened for 
potential inclusion (n=10,724)
Records excluded that did not meet the 
inclusion criteria on reviewing the titles 
and abstracts (n=10,658)
Total number of studies included in 
systematic review after full review 
of studies (n=21)
Fig. 1 Flow diagram of study
inclusion (following PRISMA
2009 recommendations)
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[95% CI 1.79, 3.80]). In studies that adjusted for age in the
pre-eclampsia and control groups, there was a statistically sig-
nificant increased risk of both any diabetes in the pooled
analysis (aRR 2.35 [95%CI 1.87, 2.95]) and of type 2 diabetes
(aRR 2.37 [95% CI 1.37, 4.10]). Further sensitivity analyses
were performed with studies that either excluded or adjusted
for gestational diabetes. There was a statistically significant
increased risk of any diabetes in the pooled analysis (aRR 2.36
[95% CI 1.94, 2.88]). ESM Figs 7–10 show the individual
Forest plots for the data presented in Table 2.
The full metabolic risk factor profile of the pre-eclampsia
and control populations is shown in ESM Table 5. There were
significant differences in age, BP and BMI between the pre-
eclampsia and control groups at their follow-up in five [11, 12,
21, 26, 30], eight [11, 12, 18, 19, 25, 26, 29, 30] and six [11,
12, 19, 21, 26, 30] out of 21 studies, respectively. However,
this population consisted of only 0.5% of the total participat-
ing women, as metabolic risk factor profiles were not avail-
able in the studies that contributed the majority of participants
to this systematic review and meta-analysis [10, 22, 28, 34].
Fig. 2 Risk of diabetes with pre-
eclampsia. (a) Risk of any
diabetes with pre-eclampsia,
unadjusted and adjusted for
confounders. (b) Risk of types 1
and 2 diabetes with pre-
eclampsia. Risk estimates may
not exactly match those reported
in ESM Table 4 because of
rounding differences and
asymmetry in 95% CIs in the
original studies. IV, inverse
variance; T1DM, type 1 diabetes;
T2DM, type 2 diabetes
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Discussion
Our systematic review and meta-analysis of 21 studies, in-
cluding more than 2.8 million women, suggests that there is
an association of pre-eclampsia with future incident diabetes.
The risk of diabetes in women who had experienced pre-
eclampsia was approximately double that of women without
a history of pre-eclampsia, and increased to 2.4-fold if type 2
diabetes was considered exclusively. This effect was seen in
the first year following delivery and persisted beyond 10 years.
Diabetes is a well-known risk factor for pre-eclampsia [36].
However, pre-eclampsia has not been established as a risk
factor for future diabetes. In comparison, gestational diabetes
is a well-recognised risk factor for future diabetes. Women
with pregnancies complicated by gestational diabetes have
previously been reported to have a sevenfold increased risk
of developing type 2 diabetes compared with those with
normoglycaemic pregnancies [37]. Our study therefore
extends the literature on the association between pre-
eclampsia and diabetes.
Current research supports the link between pre-eclampsia
and future diabetes, with several national or regional registry
studies with large sample sizes and adjustment for confound-
ing factors all showing similar results [9, 10, 22, 28, 34]. The
studies that have not shown an association are mainly those
with smaller sample sizes [11, 12, 18, 19, 21, 23, 25, 26, 29,
30]. There are gaps in the current literature, in particular with
respect to the link between pre-eclampsia and type 1 diabetes.
Furthermore, it is difficult to knowwhether the association we
report here relates to confounding factors. We were unable to
fully evaluate the effects of all confounding factors and un-
dertake further sensitivity analyses due to the absence of such
data in the studies included in the current meta-analysis. For
example, only two studies adjusted for age and BMI, as well
as excluding pre-existing diabetes and hypertension in the
study populations [22, 32]. Moreover, only seven studies
Table 1 Sensitivity analysis
considering follow-up duration
and exclusion of baseline diabetes
or hypertension
Sensitivity analysis PE and risk of outcome No. studies RR (95% CI)
Length of follow-up
<1 year Adjusted risk of any DM 2 2.17 (0.71, 6.54)
T1DM 1a 1.80 (0.83, 3.92)
T2DM 1a 2.00 (1.25, 3.20)
Pooled analysis 3 1.97 (1.35, 2.87)
1–5 years Unadjusted risk of any DM 1 1.32 (0.05, 31.83)
Adjusted risk of any DM 1 3.00 (2.45, 3.67)
Pooled analysis 2 2.99 (2.44, 3.66)
6–10 years Unadjusted risk of any DM 3 7.42 (1.30, 42.30)
Adjusted risk of any DM 5 2.43 (1.72, 3.44)
T2DM 1 3.11 (2.10, 4.61)
Pooled analysis 9 2.62 (1.96, 3.50)
>10 years Unadjusted risk of any DM 3 1.80 (1.35, 2.42)
Adjusted risk of any DM 2 1.94 (1.00, 3.77)
T2DM 2 2.25 (0.90, 5.61)
Pooled analysis 7 1.95 (1.28, 2.97)
Exclusion of baseline comorbidity
Exclusion of baseline DM Unadjusted risk of any DM 5 2.14 (1.62, 2.82)
Adjusted risk of any DM 7 2.41 (1.88, 3.09)
T1DM 1a 1.80 (0.83, 3.92)
T2DM 3a 2.17 (1.08, 4.37)
Pooled analysis 15 2.34 (1.86, 2.93)
Exclusion of baseline hypertension Unadjusted risk of any DM 2 1.97 (0.22, 17.82)
Adjusted risk of any DM 6 2.55 (1.98, 3.27)
T1DM 1a 1.80 (0.83, 3.92)
T2DM 1a 2.00 (1.27, 3.14)
Pooled analysis 9 2.40 (1.97, 2.92)
a The same study with subgroups of types 1 and 2 diabetes mellitus
DM, diabetes mellitus; PE, pre-eclampsia; T1DM, type 1 diabetes; T2DM, type 2 diabetes
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either adjusted for or excluded patients with gestational dia-
betes [9, 10, 22, 28, 31–33], a known risk factor for future
diabetes and pre-eclampsia development [38]. In the few stud-
ies where adjustments for age, BMI or gestational diabetes
were made (Table 2), the risk of future type 2 diabetes
remained increased in women who had pre-eclampsia com-
pared with the control group.
The underlying mechanism for the association between
pre-eclampsia and future diabetes is unclear. Pre-eclampsia
and diabetes share common risk factors, including age older
than 40 years, obesity, hypertension and Afro-Caribbean or
South Asian ethnic origin [39, 40]. It may be that women with
pre-eclampsia have an underlying predisposition to insulin
resistance and the metabolic syndrome, and present with
pre-eclampsia as an early indicator of their adverse metabolic
phenotype over the life course.
Risk scores allow a non-invasive method of identifying
individuals at high risk of future diabetes. The ADA risk tool
takes into account age, BMI, hypertension, history of
gestational diabetes, family history of diabetes, sex and levels
of physical activity [41]. The Finnish Diabetes Risk Score
(FINDRISC) [42] is the most commonly used score in
Europe, and has been endorsed by the European Society of
Cardiology, the EASD [43] and the Public Health Agency of
Canada [44]. FINDRISC predicts the 10-year risk of develop-
ing type 2 diabetes by considering age, BMI, use of antihy-
pertensive medication, history of hyperglycaemia (including
gestational diabetes), family history of diabetes, waist circum-
ference, physical activity, and fruit and vegetable intake [42].
Currently, screening beyond history-taking to identify risk
factors for pre-eclampsia during pregnancy is not recommend-
ed by the American Congress of Obstetricians and
Gynecologists (ACOG). Risk factors recognised by ACOG
are: age older than 40 years, obesity, chronic hypertension,
diabetes (type 1 or 2), chronic renal disease, previous pre-
eclampsia, thrombophilia, systemic lupus erythematosus,
primiparity, multiple pregnancy, in vitro fertilisation and a
family history of pre-eclampsia [45]. This overlap of risk fac-
tors for developing pre-eclampsia and type 2 diabetes could
have contributed to the association of pre-eclampsia and fu-
ture diabetes we report here. Furthermore, there is likely to be
interplay between the cardiovascular and metabolic systems.
A history of pre-eclampsia is also related to poor future car-
diovascular health, while cardiovascular disease is itself a
known risk factor for diabetes [46]. In the few studies where
adjustments for age or BMI were made (Table 2), the risk of
future type 2 diabetes remained increased in women who had
pre-eclampsia compared with the control group. Nevertheless,
as highlighted above, a number of risk factors are known to
significantly increase the risk of future diabetes; none of the
studies included in this meta-analysis fully adjusted for all of
these risk factors, and so we were unable to undertake further
sensitivity analyses.
The strength of our study lies in the number of recent studies
included and the large sample size; our meta-analysis of 21
studies examined more than 2.8 million women, including
more than 72,500 women with pre-eclampsia with 845,834
patient-years of follow-up. The inclusion of more recent stud-
ies means that there is a greater likelihood of the study findings
being generalisable to current practice. The majority of the
studies were designed to examine future diabetes or insulin
resistance and the metabolic syndrome as their main outcome
(n=18), with these studies contributing 99% of the women in
our meta-analysis.
There are a number of limitations to our analysis. As with
any meta-analysis, there is an inherent limitation from publi-
cation bias, where studies with positive findings are more
likely to be published than those that show neutral outcomes.
The majority of women included were from retrospective
studies, where there is limited control over the quality of data
collected. There may have been inconsistent, incomplete or
inaccurate historical data with respect to pre-eclampsia
Table 2 Sensitivity analyses considering the risk of pre-eclampsia and
diabetes in studies that adjusted for BMI, BMI with exclusion of baseline
hypertension and diabetes, age and gestational diabetes
Adjustment No.
studies
RR (95% CI)
Adjustment for BMI
Any DM 4 2.41 (1.37, 4.24)
T1DM 1a 1.80 (0.83, 3.92)
T2DM 2a 2.53 (1.64, 3.90)
Pooled analysis 6 2.38 (1.74, 3.24)
Adjustment for BMI, excluding baseline HTN and DM
Any DM 2 3.48 (2.37, 5.10)
T1DM 1a 1.80 (0.83, 3.92)
T2DM 1a 2.00 (1.27, 3.14)
Pooled analysis 3 2.61 (1.79, 3.80)
Adjustment for age
Any DM, matched 2 6.07 (0.72, 51.38)
Any DM, adjusted 8 2.32 (1.86, 2.91)
T1DM, adjusted 1a 1.80 (0.83, 3.92)
T2DM, adjusted 4a 2.37 (1.37, 4.10)
Pooled analysis 14 2.35 (1.87, 2.95)
Adjustment for gestational diabetes
Any DM, excluding GDM, unadjusted 1 2.08 (1.57, 2.75)
Any DM, excluding GDM, adjusted 4 2.96 (2.04, 4.29)
Any DM, adjusted for GDM 1 1.82 (1.26, 2.62)
T1DM, adjusted for GDM 1a 1.80 (0.85, 3.80)
T2DM, adjusted for GDM 1a 2.00 (1.25, 3.20)
Pooled analysis 7 2.36 (1.94, 2.88)
a The same study with subgroups of types 1 and 2 diabetes mellitus
DM, diabetes mellitus; GDM, gestational diabetes; HTN, hypertension;
PE, pre-eclampsia; T1DM, type 1 diabetes; T2DM, type 2 diabetes
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diagnosis, as well as recall bias, which could have caused the
incorrect assignment of participants to case and control
groups. In addition, five studies used questionnaire data to
assess the outcome of diabetes [11, 25, 26, 29, 31]. Finally,
it is likely that significant unmeasured confounders may have
contributed to our reported association between pre-eclampsia
and future diabetes risk, as none of the studies included in this
analysis adequately adjusted for all of the risk factors that form
the basis of many of the established diabetes risk prediction
scores [41, 42].
Given the gaps in the current literature, further work is
required to examine the association between pre-eclampsia
and type 1 diabetes in particular. There is a need for studies
that use propensity-matchingmethods ormore comprehensive
adjustments for confounding factors, as well as for high-
quality studies with long-term follow-up for outcome events.
In addition, mechanistic research is required to further our
understanding of the association between pre-eclampsia and
future diabetes in order to identify risk-reduction strategies.
Our finding of an association between pre-eclampsia and
the future development of incident diabetes is clinically im-
portant, as it suggests that formal risk assessment for the future
development of diabetes using established risk scores may be
considered in pregnant women with pre-eclampsia [41, 42].
Furthermore, clinicians may find it pertinent to enquire about
a history of pre-eclampsia as a part of the metabolic and car-
diovascular assessment of women or to incorporate into risk-
prediction formulas. Since women with pre-eclampsia are al-
ready known to be at risk of future cardiovascular disease
[47], our study highlights the importance of lifestyle and
risk-factor modification, and regular monitoring of BMI and
HbA1c in these women to further reduce their cardiovascular
and metabolic risks. In line with the ACOG recommendation
to perform annual fasting glucose testing following severe
pre-eclampsia [45], we recommend a detailed cost–benefit
analysis to determine whether and when a screening pro-
gramme for diabetes in this high-risk population should be
initiated.
Conclusions Our meta-analysis of 21 studies, which included
more than 72,500 women with pre-eclampsia, showed that
pre-eclampsia is independently associated with a twofold in-
crease in future diabetes. This increased risk was observed
from 1 year following delivery and persisted beyond 10 years
postpartum. It is likely that significant unmeasured con-
founders contribute to the association that we have reported,
and that a shared adverse risk factor profile may contribute to
both pre-eclampsia and future diabetes risk. As women with
pre-eclampsia are already known to be at risk of future cardio-
vascular disease [47], our study highlights the need for edu-
cation on risk, advice about lifestyle modifications, and regu-
lar monitoring of BMI and HbA1c in women who have had
pre-eclampsia. There is also a need to evaluate a screening
programme for diabetes in this high-risk population.
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